Search

everythinglearnresearchcommunity

for

Search:↓

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

MK-5108 is safe and shows potential against tumors, especially alone.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

CTP-543 is generally safe for treating alopecia areata.

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Bicalutamide improves hair density in women safely.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

Flutamide rarely causes liver toxicity in prostate cancer patients.

The drug combination was safe and showed promise in treating advanced tumors.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Pexidartinib often causes liver issues and fatigue, especially in women.

Oral bicalutamide is safe and effective for female hair loss.

The method accurately and quickly measures silodosin and dutasteride in mixtures.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.